Skip to main content
. 2020 May 21;21:75–85. doi: 10.1016/j.omtn.2020.05.019

Figure 1.

Figure 1

High Expression of RPL32 Is Associated with Adverse Clinical Outcomes in Patients with Lung Cancer

(A) Kaplan Meier (KM) Plotter analysis indicates that increased expression of RPL32 correlates with progression and poor survival in patients with lung cancer. (B) Representative IHC staining of RPL32 in lung cancer and paracancerous tissues. A total of 160 patient samples were stained and analyzed. (C) Quantitative analysis of RPL32 IHC staining intensity in 87 paired tumor/paratumor samples. **p < 0.01. (D) Kaplan-Meier survival curves of lung cancer patients based on the scores of RPL32 IHC staining. An IHC score in tumor tissue lower than or equal to that in its paired nontumor tissue was defined as “RPL32 Expression Low,” and the IHC score in tumor higher than its paired nontumor tissue was defined as “RPL32 Expression High.” A higher intensity of RPL32 immunostaining in tumors than in paired nontumor samples was strongly associated with poor patient survival, p = 0.0247. (E) Multivariate overall survival analysis of patients obtained by using a Cox proportion hazards model.